药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长
周五（6月20日），药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长。
消息面上，6月4日，药明巨诺宣布，其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请（NDA）获得中国澳门药物监督管理局批准。公司上月底也曾公布，国家药监局已受理细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(r/r LBCL)患者的新适应症上市许可申请。
公司此前表示，2024年下半年，公司的商业团队在人员与架构方面均进行了调整。目前已建立强劲的商业团队，负责倍诺达在中国的商业化。商业团队具备强大的商业化能力，涵盖销售团队、市场团队、市场准入及创新支付团队以及 CAR-T顾问团队。公司预计下一期间倍诺达的销售收入会再次增加，倍诺达具有卓越的产品特性，可为患者带来突破性价值，并预期更多的适应症获批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10